A short 🧵on a recent study by @MaggieLind2 with @MHitchingsEpi @datcummings Albert Ko et al. Data show that immunity induced by vaccines, prior infection or both (hybrid) protects against SARS-CoV-2 infection when viral exposure is low to moderate (1/)
Question being asked: What is the risk of becoming *infected* with SARS-CoV-2 after developing immunity following a vaccine, prior infection, or both if exposure to the virus is very high, moderate, or low? They did not study the severity of symptoms. (2/)
How? The authors used the existing database of the Connecticut Department of Correction, where infection data based on high frequency of testing for SARS-CoV-2 on ~9300 residents across 13 facilities were available. (3/)
What did they find? Prior infection, vaccination, or both provided significant protection against infection when the exposure was moderate (index case was within their cellblock) or low (no exposure was documented in cellblock co-residents) against Delta or Omicron. (4/)
However, when the viral exposure was intense (with infected cellmate - exposure is 24/7), none of these groups had enough immunity to protect against infection with Delta or Omicron virus. (5/)
These findings suggest that protection conferred by prior infection and vaccination is dependent on the cumulative viral exposure dose. An important question for the future is to determine how much the viral load vs. duration of exposure plays a key role. (6/)
If the protection is indeed dose-dependent, coupling non-pharmaceutical interventions with vaccination would be beneficial because the non-pharmaceutical intervention (masking, ventilation, etc..) reduces viral exposure, resulting in improved levels of conferred protection. (7/)
More broadly, this study answers a fundamental question on the nature of immunity. While the field speculated that immune protection against infection is exposure dose-dependent, data in support were limited. Now this study directly demonstrated this for COVID. (8/)
Their findings suggest the “need for layered interventions to mitigate SARS-CoV-2 spread, especially within dense settings, such as congregate settings, and in settings where prolonged contact is likely, such as households with infected people.” An important message to end 🧵
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Myocarditis is a rare adverse event that occurs most frequently in adolescent and young adult males after the second dose of mRNA vaccines. However, the underlying mechanisms remain unclear. (2/)
We considered three possible immune mechanisms of myocarditis. 1) Autoimmune/molecular mimicry 2) Hypersensitivity/eosinophilic type 2 immunity 3) Cytokine-mediated lymphocyte/macrophage activation
(3/)
Very excited that our PaxLC clinical trial on #longCOVID patients is now open, led by @hmkyale! This is a phase 2, 1:1 randomized, double-blind, placebo-controlled research study in 100 non-hospitalized highly symptomatic long COVID. (1/)
We will be providing paxlovid or placebo pills in long haulers for 15 days. The primary outcome will be measured by asking the patients to fill out some questionnaires pre & post treatment. We will find out whether their health changes with paxlovid vs. placebo. (2/)
Before, during, and after treatment, we will do a deep dive immune profiling to see if any changes are detected due to Paxlovid. We will apply a similar strategy that we used in our study with @PutrinoLab to understand the immune and viral signatures (3/)
A very interesting paper from Dr. Mark Davis’ group shows that in response to the mRNA vaccine, CD8 T cell responses are attenuated in people who had prior COVID compared to uninfected people. What does this mean? (1/)
Fei Gao, @VMallajosyula et al used SARS-CoV-2 pMHC-spheromers to detect viral antigen-specific CD8 and CD4 T cells from people who were vaccinated, infected or both. Spheromers are peptide-MHC multimers (12 units) that are more sensitive than conventional pMHC tetramers. (2/)
CD8 T cell responses to viral antigens were compared in people who received the mRNA vaccines to those with prior infection with SARS-CoV-2. The vaccine induced significantly better CD8 T cell immunity in both quantity and quality than the infection. (3/)
Does the innate immune system recognize metastatic cells and control their growth?
@weizmano et al found that type 2 dendritic cells and natural killer cells orchestrate very early immunity against metastatic cancer cells in the lung 👇🏽 (1/)
Adaptive immune system is important to ultimately eliminate cancer cells. However, what happens in the first days after metastatic cells arrive in a target tissue? @weizmano looked at the first 3 days after metastasis and found leukocyte recruitment around the cancer cell. (2/)
Next, @weizmano used various mice with depletion in dendritic cell types and found that CD11b+ dendritic cells (but not monocytes, CD301b+, or DC1) were required to contain the rapid growth of metastatic cells. (3/)
A while ago, @MiyuMoriyama et al showed that SARS-CoV-2 variants suppress MHC I levels in infected cells to the same degree as the ancestral virus. Then came the Omicron variants. A short update. (1/) biorxiv.org/content/10.110…
Since the original submission, @MiyuMoriyama, with the help of @NathanGrubaugh's team & @carolilucas, obtained and analyzed the ability of Omicron subvariants shown here 👇🏽 Miyu gated on spike-positive (infected) cells and compared MHC I levels to uninfected (S-) cells. (2/)
Note that MHC I surface levels are only downregulated in the infected (S+) cells, but not in the uninfected cells (S-) in the same tissue culture wells. SARS-CoV-2 evades recognition of the infected cells by cytotoxic T cells but has no impact on the surrounding cells. (3/)
Very excited to share our latest research on immunological features of #LongCovid. Our 2+ year collaboration with @PutrinoLab with many other fantastic colleagues and patients - Mount Sinai Yale Long COVID (MY-LC) study by @sneakyvirus1 et al. 🧵(1/)
There are multiple hypotheses behind long COVID pathogenesis including persistent virus/viral remnants, autoimmunity, dysbiosis, virome reactivation and tissue damage. Our data will dive deep into some of these. (3/)